Inhibition of UII/UTR System Relieves Acute Inflammation of Liver through Preventing Activation of NF-κB Pathway in ALF Mice

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Liang, Dong yu ^a   Liu, Liang ming ^a   Ye, Chang gen ^a   Zhao, Liang ^a   Yu, Fang ping ^a   Gao, De yong ^a   Wang, Ying ying ^a   Yang, Zhi wen ^a   Wang, Yan yan ^a  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BETA ACTIN; CASPASE 3; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MESSENGER RNA; NEUROTENSIN RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; URANTIDE; UROTENSIN II; AUTACOID; CYTOKINE; G PROTEIN COUPLED RECEPTOR; GALACTOSAMINE; PEPTIDE FRAGMENT; UROTENSIN; UROTENSIN II (4-11), PEN(5)-TRP(7)-ORN(8)-; UROTENSIN II RECEPTOR, MOUSE;

ACUTE LIVER FAILURE; APOPTOSIS; ARTICLE; CELL INFILTRATION; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; GEL MOBILITY SHIFT ASSAY; HEPATITIS; LIVER INJURY; LIVER PROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECTS; INFLAMMATION; LIVER; MALE; METABOLISM; PATHOLOGY;

MUS;

ANIMALS; CYTOKINES; GALACTOSAMINE; INFLAMMATION; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; LIVER; LIVER FAILURE, ACUTE; MALE; MICE, INBRED BALB C; NF-KAPPA B; PEPTIDE FRAGMENTS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; UROTENSINS;

EID: 84878626117     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064895     Document Type: Article

References (44)

1. Rutherford A, King LY, Hynan LS, Vedvyas C, Lin W, et al. (2012) Development of an accurate index for predicting outcomes of patients with acute liver failure. Gastroenterology 143: 1237-1243.
2. Lee WM, (2012) Acute liver failure. Semin Respir Crit Care Med 33: 36-45.
3. Hadem J, Strassburg CP, Manns MP, (2012) Prediction of outcome and selection of the liver transplantat candidate in acute liver failure. Front Physiol 3: 340.
4. Nakama T, Hirono S, Moriuchi A, Hasuike S, Nagata K, et al. (2001) Etoposide prevents apoptosis in mouse liver with D-galactosamine/lipopolysaccharide-induced fulminant hepatic failure resulting in reduction of lethality. Hepatology 33: 1441-1450.
5. Liu LM, Zhang JX, Wang XP, Guo HX, Deng H, et al. (2010) Pim-3 protects against hepatic failure in D-galactosamine (GalN)-sensitized rats. Eur J Clin Invest 40: 127-138.
6. Liu D, Li C, Chen Y, Burnett C, Liu XY, et al. (2004) Nuclear import of proinflammatory transcription factors is required for massive liver apoptosis induced by bacterial lipopolysaccharide. J Biol Chem 279: 48343-48442.
7. Mignon A, Rouquet N, Fabre M, Martin S, Pages JC, et al. (1999) LPS challenge in D-galactosamine-sensitized mice accounts for caspase-dependent fulminant hepatitis, not for septics hock. Am J Respir Crit Care Med 159: 1308-1315.
8. Fukuda T, Mogami A, Tanaka H, Yoshikawa T, Hisadome M, et al. (2006) Y-40138, a multiple cytokine production modulator, protects against D-galactosamine and lipopolysaccharide-induced hepatitis. Life Sci 79: 822-827.
9. Kuhla A, Eipel C, Siebert N, Abshagen K, Menger MD, et al. (2008) Hepatocellular apoptosis is mediated by TNF-α-dependent Fas/FasLigand cytotoxicity in a murine model of acute liver failure. Apoptosis 13: 1427-1438.
10. Wu Z, Han M, Chen T, Yan W, Ning Q, (2010) Acute liver failure: mechanisms of immune-mediated liver injury. Liver Int 30: 782-794.
11. Leifeld L, Clemens C, Sauerbruch T, Trebicka J, Sauerbruch T, et al. (2010) Expression of urotensin II and its receptor in human liver cirrhosis and fulminant hepatic failure. Dig Dis Sci 55: 1458-1464.
12. Pearson D, Shively JE, Clark BR, Geschwind II, Barkley M, et al. (1980) Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci USA 77: 5021-5024.
13. Douglas SA, Dhanak D, Johns DG, (2004) From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci 25: 76-85.
14. Coulouarn Y, Lihrmann I, Jegou S, Anouar Y, Tostivint H, et al. (1998) Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc. Natl. Acad. Sci. USA 95: 15803-15808.
15. Coulouarn Y, Jegou S, Tostivint H, Vaudry H, Lihrmann I, (1999) Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors. FEBS Lett 457: 28-32.
16. Ross B, McKendy K, Giaid A, (2010) Role of Urotensin II in health and disease. Am J Physiol Regul Integr Comp Physiol 298: R1156-1172.
17. Kiss RS, You Z, Genest J, Behm DJ, Giaid A, (2011) Urotensin II differentially regulates macrophage and hepatic cholesterol homeostasis. Peptides 32: 956-963.
18. Rodrigo R, Gonzalez J, Paoletto F, (2011) The role of oxidative stress in the pathophysiology of hypertension. Hypertens Res 34: 431-440.
19. Chai SB, Li XM, Pang YZ, Qi YF, Tang CS, et al. (2010) Increased plasma levels of endothelin-1 and urotensin-II in patients with coronary heart disease. Heart Vessels 25: 138-143.
20. Ng LL, Loke I, O'Brien RJ, Squire IB, Davies JE (2002) Plasma urotensin in human systolic heart failure. Circulation 106, 2877-2880.
21. Gruson D, Rousseau MF, Ketelslegers JM, Hermans MP, (2010) Raised plasma urotensin II in type 2 diabetes patients in associated with the metabolic syndrome phenotype. J Clin Hypertens (Greenwich) 12: 653-660.
22. Romanelli RG, Laffi G, Vizzutti F, Del BR, Marra F, et al. (2011) Elevated plasma levels of urotensin II do not correlate with systemic haemodynamics in patient with cirrhosis. Dig Liver Dis 43: 314-318.
23. Watanabe T, Arita S, Shiraishi Y, Suguro T, Sakai T, et al. (2009) Human urotensin II promotes hypertension and atherosclerotic cardiovascular diseases. Cur Med Chem 16: 550-563.
24. Desai N, Sajjad J, Frishman WH, (2008) Urotensin II: a new pharmacologic target in the treatment of cardiovascular disease. Cardiology in Review 16: 142-153.
25. Segain JP, Rolli-Derkinderen M, Gervois N, Raingeard de la Blétière D, Loirand G, et al. (2007) Urotensin II is a new chemotactic factor for UTR-expressing monocytes. J Immunol 179: 901-909.
26. Cirillo P, De Rosa S, Pacileo M, Gargiulo A, Angri V, et al. (2008) Human urotensin II induces tissue factor and cellular adhesion molecules expression in human coronary endothelial cells: an emerging role for urotensin II in cardiovascular disease. J Thromb Haemost 6: 726-736.
27. Johns DG, Ao Z, Naselsky D, Herold CL, Maniscalco K, et al. (2004) Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol 370: 238-250.
28. Zhang JY, Chen ZW, Yao H, (2012) Protective effect of urantide against ischemia-reperfusion injury via protein kinase C and phosphtidylinositol 3′-kinase - Akt pathway. Can J Physiol Pharmacol 90: 637-645.
29. Leifeld L, Trautwein C, Dumoulin FL, Manns MP, Sauerbruch T, et al. (1999) Enhanced expression of CD80 (B7-1), CD86 (B7-2), and CD40 and their ligands CD28 and CD154 in fulminant hepatic failure. Am J Pathol 154: 1711-1720.
30. Porstmann T, Kiessig ST, (1992) Enzyme immunoassay techniques: an overview. J Immunol Methods 150: 5-21.
31. Chen Q, Chen T, Li W, Zhang W, Zhu J, et al. (2012) Mycoepoxydiene inhibits lipopolysaccharide-induced inflammatory responses through the of TRAF6 polyubiquitination. PLoS One 7: e44890.
32. Balat A, Buyukcelik M, (2012) Urotensin-II: more than a mediator for kidney. Int J Nephrol 2012: 249790.
33. Dong X, Ye X, Song N, Zhao J, Di B, et al. (2012) Urotensin II promotes the production of LTC(4) in rat aortic adventitial fibroblasts through NF-κB-5-LO pathway by p38 MAPK and ERK activations. Heart Vessels. [Epub ahead of print].
34. Trebicka J, Leifeld L, Hennenberg M, Biecker E, Eckhardt A, et al. (2008) Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. Hepatology 47: 1264-1276.
35. Zimmermann HW, Trautwein C, Tacke F, (2012) Functional role of monocytes and macrophages for the inflammatory response in acute injury. Front Physiol 3: 56.
36. Meurs M, Castro P, Shapiro NI, Lu S, Yano M, et al. (2012) Adiponectin diminishes organ-specific microvascular endothelial cell activation associated with sepsis. Shock 37: 392-398.
37. Robaczewska M, Boukhadra C, Studer R, Mueller C, Binkert C, et al. (2003) The expression of urotensin II receptor (U2R) is up-regulated by interferon-gamma. J Recept Signal Transduct Res 23: 289-305.
38. Didonato JA, Mercurio F, Karin M, (2012) NF-κB and the link between inflammation and cancer. Immunol Rev 246: 379-400.
39. Hayden MS, Ghosh S, (2012) NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 26: 203-234.
40. Sun D, Chen D, Du B, Pan J, (2005) Heat shock response inhibits NF-kappaB activation and cytokine production in murine Kupffer cells. J Surg Res 129: 114-121.
41. Dyson HJ, Komives EA, (2012) Role of disorder in IκBα-NF-κB interaction. IUBMB Life 64: 499-505.
42. Cervantes CF, Bergqvist S, Kjaergaard M, Kroon G, Sue SC, et al. (2011) The RelA nuclear localization signal folds upon binding to IκBα. J Mol Biol 405: 754-764.
43. Deng T, Feng X, Liu P, Yan K, Chen Y, et al. (2012) Toll-like receptor 3 activation differentially regulates phagocytosis of bacteria and apoptotic neutrophils by mouse peritoneal macrophage. Immunol Cell Biol In press.
44. Ren S, Zhang S, Li M, Huang C, Liang R, et al. (2012) NF-κB p65 and c-Rel subunits promote phagocytosis and cytokine secretion by splenic macrophages in cirrhotic patients with hypersplenism. Int J Biochem Cell Biol 45: 335-343.